Abstract
The cellular mechanism of action of tedisamil (KC-8857) (TED), a novel antiarrhythmic / antifibrillatory compound, was studied on transmembrane currents in guinea pig, rabbit and dog ventricular myocytes by applying the patch-clamp and the conventional microelectrode technique. In guinea pig myocytes the rapid component of the delayed rectifier potassium current (IKr) was largely diminished by 1 μM TED (from 0.88±0.17 to 0.23±0.07 pA / pF, n=5, p < 0.05), while its slow component (IKs) was reduced only by 5 μM TED (from 8.1±0.3 to 4.23±0.07 pA / pF, n=5, p < 0.05). TED did not significantly change the IKr and IKs kinetics. In rabbit myocytes 1 μM TED decreased the amplitude of the transient outward current (Ito) from 20.3±4.9 to 13.9±2.8 pA / pF (n=5, p < 0.05), accelerated its fast inactivation time constant from 8.3±0.6 to 3.5±0.5 ms (n=5, p < 0.05) and reduced the ATP-activated potassium current (IKATP) from 38.2±11.8 to 18.4±4.7 pA / pF (activator: 50 μM cromakalim; n=5, p < 0.05). In dog myocytes 2 μM TED blocked the fast sodium current (INa) with rapid onset and moderately slow offset kinetics, while the inward rectifier potassium (IK1), the inward calcium (ICa) and even the Ito currents were not affected by TED in concentration as high as 10 μM. The differences in Ito responsiveness between dog and rabbit are probably due to the different α-subunits of Ito in these species. It is concluded that inhibition of several transmembrane currents, including IKr, IKs, Ito, IKATP and even INa, can contribute to the high antiarrhythmic / antifibrillatory potency of TED, underlying predominant Class III combined with I A / B type antiarrhythmic characteristics.
Keywords: tedisamil (kc-8857), cellular mechanism of action, transmembrane ion currents, cardiomyocytes
Current Medicinal Chemistry
Title: Effect of the Antifibrillatory Compound Tedisamil (KC-8857) on Transmembrane Currents in Mammalian Ventricular Myocytes
Volume: 11 Issue: 24
Author(s): N. Jost, L. Virag, O. Hala, A. Varro, D. Thormahlen and J. Gy. Papp
Affiliation:
Keywords: tedisamil (kc-8857), cellular mechanism of action, transmembrane ion currents, cardiomyocytes
Abstract: The cellular mechanism of action of tedisamil (KC-8857) (TED), a novel antiarrhythmic / antifibrillatory compound, was studied on transmembrane currents in guinea pig, rabbit and dog ventricular myocytes by applying the patch-clamp and the conventional microelectrode technique. In guinea pig myocytes the rapid component of the delayed rectifier potassium current (IKr) was largely diminished by 1 μM TED (from 0.88±0.17 to 0.23±0.07 pA / pF, n=5, p < 0.05), while its slow component (IKs) was reduced only by 5 μM TED (from 8.1±0.3 to 4.23±0.07 pA / pF, n=5, p < 0.05). TED did not significantly change the IKr and IKs kinetics. In rabbit myocytes 1 μM TED decreased the amplitude of the transient outward current (Ito) from 20.3±4.9 to 13.9±2.8 pA / pF (n=5, p < 0.05), accelerated its fast inactivation time constant from 8.3±0.6 to 3.5±0.5 ms (n=5, p < 0.05) and reduced the ATP-activated potassium current (IKATP) from 38.2±11.8 to 18.4±4.7 pA / pF (activator: 50 μM cromakalim; n=5, p < 0.05). In dog myocytes 2 μM TED blocked the fast sodium current (INa) with rapid onset and moderately slow offset kinetics, while the inward rectifier potassium (IK1), the inward calcium (ICa) and even the Ito currents were not affected by TED in concentration as high as 10 μM. The differences in Ito responsiveness between dog and rabbit are probably due to the different α-subunits of Ito in these species. It is concluded that inhibition of several transmembrane currents, including IKr, IKs, Ito, IKATP and even INa, can contribute to the high antiarrhythmic / antifibrillatory potency of TED, underlying predominant Class III combined with I A / B type antiarrhythmic characteristics.
Export Options
About this article
Cite this article as:
Jost N., Virag L., Hala O., Varro A., Thormahlen D. and Papp Gy. J., Effect of the Antifibrillatory Compound Tedisamil (KC-8857) on Transmembrane Currents in Mammalian Ventricular Myocytes, Current Medicinal Chemistry 2004; 11 (24) . https://dx.doi.org/10.2174/0929867043363631
DOI https://dx.doi.org/10.2174/0929867043363631 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update
Current Vascular Pharmacology Speculative Considerations about Some Cardiology Enigmas
Current Cardiology Reviews Obesity Paradox in Atrial Fibrillation and its Relation with the New Oral Anticoagulants
Current Cardiology Reviews Editorial (Thematic Issue: Perspectives of Antiarrhythmic Therapy: New Trails, Challenges and Pitfalls)
Current Pharmaceutical Design Vitamin D Biology in Heart Failure: Molecular Mechanisms and Systematic Review
Current Drug Targets Possible Exploitation of Non-Neuronal and Non-Chemical Synaptic Signalling Pathways in Epilepsy Therapy
Current Signal Transduction Therapy Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease
Current Drug Targets Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art
Current Drug Targets Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science New Proposals for Testing Drugs with IKr-Blocking Activity to Determine Their Teratogenic Potential
Current Pharmaceutical Design Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews New Electrocardiographic Features in Brugada Syndrome
Current Cardiology Reviews Strategic Leukofiltration in Cardiac Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches
Current Medicinal Chemistry Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
Current Medicinal Chemistry Henoch Schonlein Purpura in Childhood
Current Pediatric Reviews Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design